Phase II trial of Afatinib as induction treatment in patients with stage IIIA or stage IIIB N2 requiring neoadjuvant treatment for pN2 non squamous non small cell lung cancer (NSCLC) with EGFR-activating mutations.
Latest Information Update: 11 Mar 2024
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Mar 2024 Status changed from recruiting to discontinued.
- 05 Aug 2021 New trial record